Pfizer Battles 2nd FCA Suit Over Antifungal Drug Promotions

Law360, New York (June 13, 2012, 8:33 PM EDT) -- A Massachusetts federal judge Monday unsealed an ex-Pfizer Inc. manager's False Claims Act suit accusing the drug giant of a long-running and illegal campaign to promote off-label use of antifungal drugs, echoing similar allegations in a complaint last year.

Paul Worsfold, a former district manager at Pfizer, says his ex-employer recklessly and unnecessarily endangered patient health by encouraging unapproved uses of Vfend and Eraxis.

Alleged offenses include promoting off-label treatment in children under 12 and in individuals with neutropenia, a blood disorder commonly caused by cancer...
To view the full article, register now.




Case Information

Case Title

United States of America et al v. Pfizer Inc

Case Number




Nature of Suit

Other Statutory Actions


Nathaniel M. Gorton

Date Filed

September 11, 2009

Law Firms


UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.